相关实验视频

Updated: Sep 11, 2025

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

奎尔素作为一种有前途的治疗剂对抗2型糖尿病的潜力

Przemysław Niziński¹, Anna Hawrył², Paweł Polak³

¹Department of Pharmacology, Medical University of Lublin, Radziwiłłowska 11, 20-080 Lublin, Poland.

Molecules (Basel, Switzerland)

|August 14, 2025

概括

Quercetin 是一种天然的黄类化合物,通过改善胰岛素敏感性和保护免受并发症,在治疗糖尿病方面表现有前途. 目前正在开发配方策略,以克服其低生物可用性,以增强治疗用途.

科学领域:

药理学药理学是指药理学的学科.
营养保健品营养保健品
生物化学生物化学

背景情况:

糖尿病是一种全球性健康问题,患病率越来越高.
Quercetin (QE) 是一种植物衍生的黄类化合物,具有显著的药理活性.
由于其对血糖控制的有益影响,QA的抗糖尿病潜力越来越受关注.

研究的目的:

阐明奎尔丁抗糖尿病作用的机制基础.
在糖尿病中审查瑞调节的分子通路.
讨论在临床环境中增强奎尔丁治疗功效的策略.

主要方法:

审查关于奎尔塞丁药理作用的现有文献.
分析基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因
探索配方策略,以提高奎尔塞丁的生物可用性.

主要成果:

奎瑞通过增强胰岛素敏感性,葡萄糖吸收和β细胞功能来改善血糖控制.
它调节关键的分子通路 (AMPK,PI3K/Akt,Nrf2/ARE) 并抑制氧化应激和炎症 (TNF-α,IL-6).
奎思可以缓解糖尿病并发症,包括病,视网膜病和血管功能障碍.

结论:

奎尔素通过多种分子机制显示出显著的抗糖尿病特性.
低生物可用性和可溶性限制了奎尔塞丁的临床应用.
先进的配方技术有望改善奎尔的药理动力学特征和治疗潜力.

关键词:

抗氧化剂抗氧化剂是一种抗氧化剂.功能性食品是一种功能性食品.营养保健品营养保健品氧化应激是一种氧化应激.聚醇是一种多醇.文素 (Quercetin) 是一种文素.

更多相关视频

Extraction and Analysis of Taiwanese Green Propolis

Extraction and Analysis of Taiwanese Green Propolis

Published on: January 7, 2019

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

相关概念视频

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Carbohydrate Metabolism

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...